NOXXON Pharma N.V. announced the resignation of Gregory Weaver from its Supervisory Board, effective September 30, 2022. Mr. Weaver is transitioning away from some of his professional commitments to allow room to focus on his Chief Financial Officer career, leading to scaling back on his other professional obligations. He has served as a member of NOXXON's Supervisory Board since June 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.314 EUR | 0.00% | -7.10% | +36.52% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+36.52% | 9.46M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |
- Stock
- Equities
- Stock TME Pharma N.V. - Euronext Paris
- News TME Pharma N.V.
- NOXXON Pharma N.V. Announces Resignation of Gregory Weaver from its Supervisory Board, Effective September 30, 2022